Paclitaxel, Epirubicin and Capecitabine (TEX) as First-Line Treatment for Metastatic Breast Cancer: a Pilot Phase I/II Feasibility Study

被引：0
|
作者：
Einbeigi, Z. [1 ]
Bergstrom, D. [2 ]
Hatschek, T. [3 ]
Malmberg, M. [4 ]
机构：
[1] Sahlgrens Univ Hosp, Dept Oncol, S-41345 Gothenburg, Sweden
[2] Roche AB, Stockholm, Sweden
[3] Karolinska Univ Hosp, Radiumhemmet, Stockholm, Sweden
[4] Helsingborg Hosp, Dept Oncol, Helsingborg, Sweden
来源：
CLINICAL MEDICINE INSIGHTS-ONCOLOGY | 2008年 / 2卷
关键词：
epirubicin; paclitaxel; capecitabine; first-line chemotherapy; metastatic breast cancer; phase I/II;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m(2), paclitaxel 155 mg/m(2) (both day 1) and capecitabine 665 mg/m(2) twice daily (days 1- 14) every 21 days, with intra-patient dose escalation/reduction. Grade 3/4 events were infrequent. Nine patients (69%) achieved an objective response. Median time to progression and overall survival were 6.6 and 23.5 months, respectively.
引用
收藏
页码：533 / 538
页数：6
相关论文
共 50 条
  • [1] Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer
    Luck, HJ
    Thomssen, C
    duBois, A
    Untch, M
    Lisboa, B
    Kohler, G
    Diergarten, K
    [J]. SEMINARS IN ONCOLOGY, 1997, 24 (05) : 35 - 39
  • [2] Preliminary results of a phase II study of epirubicin and paclitaxel as first-line treatment in patients with metastatic breast cancer
    Luck, HJ
    Thomssen, C
    duBois, A
    Lisboa, BW
    Untch, M
    Kuhnle, H
    Janicke, F
    Meerpohl, HG
    Lindner, C
    Kcnecny, G
    Hecker, D
    Diergarten, K
    [J]. SEMINARS IN ONCOLOGY, 1997, 24 (01) : S13 - S16
  • [3] Optimizing doses of a first line chemotherapy treatment containing epirubicin, paclitaxel and capecitabine (TEX) in metastatic breast cancer.
    Einbeigi, Z
    Bergström, D
    Hatschek, T
    Malmberg, M
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S131 - S131
  • [4] Phase II trial of capecitabine and weekly paclitaxel as first-line therapy for metastatic breast cancer
    Blum, Joanne L.
    Dees, E. Claire
    Chacko, Aparna
    Doane, Lisa
    Ethirajan, Sukumar
    Hopkins, Judith
    McMahon, Richard
    Merten, Suzan
    Negron, Angel
    Neubauer, Marcus
    Ilegbodu, Des
    Boehm, Kristi A.
    Asmar, Lina
    O'Shaughnessy, Joyce A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (27) : 4384 - 4390
  • [5] Interim analysis of a phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer
    Luck, HJ
    Thomssen, C
    duBois, A
    Lisboa, BW
    Untch, M
    Kuhnle, H
    Konecny, G
    Janicke, F
    Meerpohl, HG
    Lindner, C
    Hecker, D
    Diergarten, K
    [J]. SEMINARS IN ONCOLOGY, 1996, 23 (01) : 33 - 36
  • [6] Phase II study of vinorelbine and capecitabine as first-line treatment for metastatic breast cancer.
    El-Sadda, Wael
    Halim, Inas Ibraheim Abdel
    Aziz, Mohamed Abdel
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] BIWEEKLY PACLITAXEL AND CISPLATIN - A PHASE-I/II STUDY IN THE FIRST-LINE TREATMENT OF METASTATIC BREAST-CANCER
    OREILLY, SE
    GELMON, KA
    [J]. SEMINARS IN ONCOLOGY, 1995, 22 (03) : 109 - 111
  • [8] A phase I-II study of bi-weekly paclitaxel as first-line treatment in metastatic breast cancer
    Gelmon, KA
    Tolcher, A
    O'Reilly, S
    Campbell, C
    Bryce, C
    Shenkier, T
    Ragaz, J
    Ayers, D
    Nakashima, L
    Rielly, S
    Dulude, H
    [J]. ANNALS OF ONCOLOGY, 1998, 9 (11) : 1247 - 1249
  • [9] Paclitaxel, epirubicin and cyclophosphamide combination in first-line treatment of metastatic breast cancer: A dose escalation study
    Bonneterre, J
    Tubiana-Hulin, M
    Catimel, G
    [J]. ONCOLOGY, 2004, 66 (03) : 185 - 191
  • [10] Individually tailored treatment with epirubicin and paclitaxel with or without capecitabine as first-line chemotherapy in metastatic breast cancer: a randomized multicenter trial
    T. Hatschek
    L. Carlsson
    Z. Einbeigi
    E. Lidbrink
    B. Linderholm
    B. Lindh
    N. Loman
    M. Malmberg
    S. Rotstein
    M. Söderberg
    M. Sundquist
    T. M. Walz
    M. Hellström
    H. Svensson
    G. Åström
    Y. Brandberg
    J. Carstensen
    M. Fernö
    J. Bergh
    [J]. Breast Cancer Research and Treatment, 2012, 131 : 939 - 947
12345